Google+ Badge

Thursday, March 19, 2015

Cancer Research: Lethal subtype of prostate cancer ♦ New genome-editing technology ♦ Cancer-targeted treatment in triple combo drug for melanoma + more

Study identifies 'lethal' subtype of prostate cancer  Of prostate cancer patients with combination MAP3K7 and CHD1 deletions, about 50 percent will have recurrent prostate cancer, which ultimately leads to death, a study concludes. About 10 percent of all prostate cancers harbor combined MAP3K7-CHD1 deletions Continue Reading
New genome-editing technology to help treat blood cancers  A new genome editing technology has been developed that can target and kill blood cancer cells with high accuracy. Using the technology,they were able to kill human lymphoma cells by locating and deleting an essential gene for cancer cell survival Continue Reading
Link between aspirin, NSAIDs and colon cancer prevention may hinge on genetic variations  The link between taking aspirin, non-steroidal anti-inflammatory drugs, or NSAIDS, and colorectal cancer prevention is well established, but the mechanisms behind the protective effect have not been understood. A new study suggests this protection differs according to variations in DNA.Continue Reading
Benefits of immunotherapy, cancer-targeted treatment in triple combo drug for melanoma  Groundbreaking new triple combination therapy shows signs of more effectively controlling advanced melanoma than previous BRAF + MEK inhibitor or BRAF inhibitor + immunotherapy combos alone, and with fewer side effects Continue Reading
Scientists pioneer new drug regimen that reduces toxicities for renal cancer patients Conclusive results have been revealed in reducing toxicities for Asian patients with cancer that has spread beyond the kidney. The findings have revolutionized the standard protocol for patient management  Continue Reading

No comments:

Post a Comment